Logo

Tempus

Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors

Tempus will screen patients sequenced through its platform for PALB2 mutations to accelerate trial enrollment.

In Brief This Week: Orgenesis, Veracyte, Scorpion, Viracta, Tempus, Labcorp

News items for the week of Nov. 29, 2021.

In Brief This Week: Northwell Health, Tempus, CARsgen, Baptist Cancer Center, HTG Molecular Diagnostics

News items for the week of Nov. 15, 2021.

In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio

News items for the week of Nov 8, 2021.

Cedars-Sinai, Tempus Partner on Molecular Database Initiative

The partners launched the Molecular Twin initiative to collect cancer patients' DNA, RNA, and protein information and use it to inform treatment and advance research.

Aug 17, 2021

Tempus Submits PMA Application for Tumor Profiling Assay to FDA

Jun 3, 2021

Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial

Mar 3, 2021

Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership

Feb 25, 2021

Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

Feb 25, 2021

Zentalis Pharmaceuticals, Tempus Partner to Explore WEE1 Inhibitor Activity in Organoid Models

Jan 27, 2021

Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

Jan 13, 2021

Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity

Jan 12, 2021

JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More

Jan 5, 2021

Precision Oncology in 2020: Pandemic Lessons, Biomarker Controversies, Community Access Gaps
Premium

Dec 14, 2020

Hummingbird Biosciences, Tempus Partner to ID Cancer Patients for Anti-HER3 Treatment Trial

Dec 10, 2020

Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer

Dec 9, 2020

Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project

Nov 23, 2020

Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

Nov 2, 2020

Tempus, Janssen R&D Collaborate on Oncology Clinical Trial Matching

Oct 13, 2020

Pancreatic Cancer Action Network Launches Adaptive Clinical Trial Platform

Sep 16, 2020

LabCorp's Covance Joins Tempus TIME Trial Program

Feb 6, 2020

Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing

May 30, 2019

Tempus Raises $200M in Series F Financing

Jan 10, 2019

Tempus, ASCO Partner to Facilitate Recruiting for TAPUR Trial

Dec 3, 2018

Tempus Ramps Up AI-Driven Precision Oncology, Eyes Other Markets
Premium